CJC-1295 DAC (2 mg) & Ipamorelin (5 mg) (Stack)
Combination protocol of CJC-1295 DAC (a long-acting GHRH analog) and Ipamorelin (a selective ghrelin agonist). Together, they synergistically enhance endogenous growth hormone and IGF-1 secretion.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
CJC-1295 DAC is a synthetic GHRH analog that stimulates pituitary GH secretion. The attachment to albumin via the Drug Affinity Complex (DAC) extends its action to 6–8 days. Ipamorelin activates the ghrelin receptor (GHSR) without affecting ACTH/cortisol. The combination acts via complementary pathways (GHRH + ghrelin) for synergistic GH enhancement.
Quick Start
- CJC-1295 DAC: Add 2.0 mL bacteriostatic water → 1.0 mg/mL; inject once weekly.
- Ipamorelin: Add 3.0 mL bacteriostatic water → 1.67 mg/mL; inject once daily.
- Storage: Lyophilized: ≤ −15 °C; reconstituted: 2–8 °C, within 3–4 weeks.
Combination Stack Protocol — Typical Approach
Route: Subcutaneous | Frequency: CJC-1295 DAC: 1×/wk | Ipamorelin: 1×/day
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | CJC: 1000 mcg (1 mg) weekly | 100 units (1.0 mL) | Ipam: 6 units (0.06 mL)/day |
| Weeks 3–4 | CJC: 1000 mcg (1 mg) weekly | 100 units (1.0 mL) | Ipam: 9 units (0.09 mL)/day |
| Weeks 5–12 | CJC: 1000 mcg (1 mg) weekly | 100 units (1.0 mL) | Ipam: 12 units (0.12 mL)/day |
CJC-1295 DAC is administered on the same day each week. Ipamorelin is administered before bedtime to synergize with nocturnal GH secretion.
Reconstitution Steps
Dilution Selection
Peptides come in 3 mL, 5 mL or 10 mL vials. If your vial is smaller, the water amount adjusts automatically.
CJC-1295 DAC (2 mg)
Ipamorelin (5 mg)
⚠️ Units change depending on BAC water — always verify before administration. Based on
- CJC-1295 DAC: Withdraw 2.0 mL BAC water → inject slowly down the vial wall → gently swirl → 1.0 mg/mL.
- Ipamorelin: Withdraw 3.0 mL BAC water → inject slowly → gently swirl → 1.67 mg/mL.
- Note the date on each vial; refrigerate at 2–8 °C.
- Use within 3–4 weeks.
Protocol Overview
- Goal: Enhance endogenous GH/IGF-1 via GHRH + ghrelin.
- Schedule: CJC-1295 DAC 1×/wk + Ipamorelin 1×/day for 8–16 wks.
- Doses: CJC: 1–2 mg/wk; Ipamorelin: 100–300 mcg/day.
- Storage: Lyophilized frozen; reconstituted refrigerated.
Dosing Protocol
- CJC-1295 DAC: 1 mg subcutaneously 1× weekly on a consistent day.
- Ipamorelin: Start at 100 mcg/day; titrate to 200 mcg in week 5.
- Timing: Ipamorelin before bed.
- Cycle: 8–12 wks typically; up to 16 wks if tolerated.
- Break between cycles: After the cycle, a pause of 4–8 weeks is recommended. The a CJC-1295 DAC + Ipamorelin combination strongly stimulates the GH axis—the pause prevents GHRH/GHSR tolerance.
Washout & Cycle Restart
When can I restart?
After the cycle, a pause of 4–8 weeks is recommended. The a CJC-1295 DAC + Ipamorelin combination strongly stimulates the GH axis—the pause prevents GHRH/GHSR tolerance.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: ≤ −15 °C; ideally ≤ −50 °C for long-term.
- Reconstituted: 2–8 °C; within 3–4 weeks; avoid freeze-thaw cycles.
Important Notes
- Do not mix the two peptides in the same vial.
- Log doses daily.
Potential Benefits & Side Effects
Potential Benefits:
- Improved body composition (muscle mass ↑, fat ↓).
- Sustained increase in GH/IGF-1 for 6–11 days per CJC dose.
- Ipamorelin selectivity without increasing cortisol.
- Good tolerability in clinical studies.
Potential Side Effects:
- Water retention, mild headache.
- Transient numbness/tingling.
- Injection site reactions.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical risk (prolonged GH elevation)
The DAC variant provides continuous GH elevation for 7–10 days. Theoretical concern for IGF-1-related oncogenesis.
📄 J Clin Endocrinol Metab 2006Fluid retention & edema
Prolonged GH elevation can cause fluid retention, arthralgia, and carpal tunnel syndrome.
📄 J Clin Endocrinol Metab 2006Theoretical risk (GH/IGF-1 elevation)
As a GHS, increases GH. Theoretical risk for pre-existing neoplasms due to IGF-1 elevation. No clinical signal in short-term studies.
📄 Growth Horm IGF Res 2008References
- J Clin Endocrinol Metab — CJC-1295: prolonged stimulation of GH/IGF-1
View Source - Eur J Endocrinol — Ipamorelin: the first selective GH secretagogue
View Source - Endocrine Reviews — GH secretagogues: mechanisms & clinical applications
View Source - Transl Androl Urol (PMC) — GH secretagogues in body composition
View Source
Recommended Supplements
L-Arginine + L-Ornithine
ZMA (Zinc + Magnesium + B6)
🧬 General Wellness
Multivitamin (High-Quality)
Magnesium Glycinate
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Probiotics (Multi-Strain)
Electrolytes (Na, K, Mg)
Liver Support (NAC / Milk Thistle)
External Sources & Regulatory Status
Regulatory Approvals
Postoperative ileus
Phase II (development discontinued)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →